Japanese journal of clinical oncology · 2026
Trends in 5-year net survival for women diagnosed with breast, cervical or ovarian cancer in Japan, 2000-14 (CONCORD-3).
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Watanabe Kaname, Di Carlo Veronica, Sugiyama Hiromi, Nakamura Sho, Chei Choy-Lye, Narimatsu Hiroto, Matz Melissa, Oki Izumi, Shibata Akiko, Nakata Kayo, Kajiwara Saito Mari, Matsuzaka Masashi, Nishio Marisa, Oze Isao, Tanaka Rina, Gatellier Laureline, Yoshida Isao, Ito Hidemi, Teramoto Norihiro, Yamashita Natsumi, Kaizaki Yasuharu, Moki Fumitaka, Kurosawa Katsuki, Nemoto Yuji, Kanemura Seiki, Miyashiro Isao, Mori Daisuke, Fujita Shin, Matsuda Tomohiro, Coleman Michel P, Allemani Claudia
Аннотация
BACKGROUND: Breast, cervical and ovarian cancers significantly affect young and middle-aged women, both physically and socially. However, relevant comprehensive stratified analyses are limited. Using Japanese data from CONCORD-3, a global cancer survival surveillance program, we analyzed long-term survival trends.
METHODS: Data from 16 Japanese population-based cancer registries were analyzed for women diagnosed aged 15-99 years during 2000-2014 with a tumor originating in the breast, cervix uteri or ovaries. Follow-up was extended to five years post-diagnosis or until December 31st, 2014. In situ tumors and death-certificate-only registrations were excluded. Five-year net survival was estimated with the Pohar Perme estimator by calendar period of diagnosis, morphology and stage, and age-standardized with International Cancer Survival Standard weights.
RESULTS: During 2000-2014, 5-year net survival improved for breast cancer from 85.9% (95% CI, 85.2-86.6%) to 89.4% (88.9-89.9%), for cervical cancer from 67.5% (66.3-68.7%) to 71.4% (70.4-72.3%), and for ovarian cancer from 35.5% (33.8-37.2%) to 46.3% (44.9-47.7%). Five-year survival for tumors diagnosed at a localized stage remained consistently high (>98% for breast cancer and > 90% for cervical cancer). Ovarian cancer survival varied greatly according to morphology.
CONCLUSIONS: Five-year net survival for women with cancers of the breast, cervix, and ovary) in Japan improved during 2000-2014, and remained at a globally high level throughout this period. These gains are probably attributable to earlier detection of breast and cervical cancers and advances in multimodal treatment for all cancers. Survival for distant-stage cervical and ovarian cancers remains a challenge, underscoring the need for enhanced screening and treatment strategies.
METHODS: Data from 16 Japanese population-based cancer registries were analyzed for women diagnosed aged 15-99 years during 2000-2014 with a tumor originating in the breast, cervix uteri or ovaries. Follow-up was extended to five years post-diagnosis or until December 31st, 2014. In situ tumors and death-certificate-only registrations were excluded. Five-year net survival was estimated with the Pohar Perme estimator by calendar period of diagnosis, morphology and stage, and age-standardized with International Cancer Survival Standard weights.
RESULTS: During 2000-2014, 5-year net survival improved for breast cancer from 85.9% (95% CI, 85.2-86.6%) to 89.4% (88.9-89.9%), for cervical cancer from 67.5% (66.3-68.7%) to 71.4% (70.4-72.3%), and for ovarian cancer from 35.5% (33.8-37.2%) to 46.3% (44.9-47.7%). Five-year survival for tumors diagnosed at a localized stage remained consistently high (>98% for breast cancer and > 90% for cervical cancer). Ovarian cancer survival varied greatly according to morphology.
CONCLUSIONS: Five-year net survival for women with cancers of the breast, cervix, and ovary) in Japan improved during 2000-2014, and remained at a globally high level throughout this period. These gains are probably attributable to earlier detection of breast and cervical cancers and advances in multimodal treatment for all cancers. Survival for distant-stage cervical and ovarian cancers remains a challenge, underscoring the need for enhanced screening and treatment strategies.